[Systemic Treatment of Early and Metastatic Breast Cancer]

Area of Science:

• Oncology
• Medical Research
• Pharmacology

Background:

• Breast cancer treatment has seen significant progress with innovative targeted therapies and drug combinations.
• Hormone receptor-positive breast cancer benefits from endocrine treatments, including CDK-4/6 inhibitors, improving progression-free survival.
• HER2-positive breast cancer treatment has advanced with combination therapies like Pertuzumab and Trastuzumab.

Purpose of the Study:

• To summarize recent advancements in early and metastatic breast cancer treatment.
• To highlight the role of targeted therapies and novel drug combinations.
• To discuss emerging strategies for different breast cancer subtypes.

Main Methods:

• Review of recent clinical trial data and therapeutic advancements.
• Analysis of targeted therapies, endocrine treatments, and combination regimens.
• Evaluation of emerging treatments for HER2-positive, triple-negative, and BRCA-mutated breast cancer.

Main Results:

• GnRH-analogues are integral to endocrine therapy for premenopausal patients.
• CDK-4/6 inhibitors significantly improve progression-free survival in metastatic breast cancer.
• Combination therapy with Pertuzumab and Trastuzumab enhances anti-HER2 treatment efficacy.
• Chemotherapy remains standard for triple-negative breast cancer, with immune checkpoint inhibitors showing promise.
• PARP inhibitors offer a new treatment avenue for BRCA1/2 mutation carriers.

Conclusions:

• Innovative targeted therapies and drug combinations have significantly improved breast cancer treatment outcomes.
• Personalized treatment strategies, including endocrine therapy, HER2-targeted agents, and emerging options like PARP inhibitors, are crucial for different breast cancer subtypes.
• Ongoing research into immune checkpoint inhibitors holds promise for triple-negative breast cancer management.